HMP19 Inhibitors
Chemical inhibitors of HMP19 can be understood through the examination of various compounds that target signaling pathways and kinases which are crucial for the protein's activity. Staurosporine is a broad-spectrum protein kinase inhibitor that can lead to reduced phosphorylation and thus diminished function of HMP19 by targeting the kinases responsible for its activation. Similarly, Chelerythrine, through its inhibition of protein kinase C (PKC), can suppress the downstream signaling that would otherwise result in the phosphorylation and subsequent activity of HMP19. This effect is also seen with other PKC inhibitors such as Bisindolylmaleimide I, Go 6983, and Ro-31-8220, which by reducing PKC activity, can directly influence the phosphorylation state and therefore the activity of HMP19. Ruboxistaurin and GF109203X, which are more selective towards PKC isoforms, particularly PKCβ in the case of Ruboxistaurin, can similarly alter the function of HMP19 by preventing its phosphorylation through these specific kinase pathways.
Further down the signaling cascade, LY294002 and Wortmannin, both phosphatidylinositol 3-kinase (PI3K) inhibitors, can disrupt the PI3K-dependent pathways that may control the activity of HMP19. By impeding the PI3K pathway, these inhibitors can affect the activity of HMP19, possibly reducing its functional output. MEK inhibitors like U0126 and PD98059 target the MAPK/ERK pathway, which is another critical route for the regulation of numerous proteins, including HMP19. By inhibiting MEK1/2, U0126 can lead to a decrease in the activity of the ERK pathway, resulting in a reduction in the activity of HMP19. PD98059 functions in a similar fashion, targeting MEK upstream of ERK, with the expectation of a similar inhibitory effect on HMP19. Lastly, SB203580 operates by inhibiting p38 MAPK, another molecule in the MAPK pathway, which can affect HMP19 function by altering the activity of proteins regulated within this signaling framework.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. HMP19's function in neurotransmission could be impacted by the inhibition of specific protein kinases that are critical for its phosphorylation state and thus its activity. Staurosporine can inhibit these kinases, leading to reduced function of HMP19. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $88.00 $311.00 | 17 | |
Chelerythrine is known to inhibit protein kinase C (PKC). Since PKC is involved in numerous signaling cascades that could regulate proteins like HMP19, its inhibition can lead to decreased phosphorylation and subsequent activity of HMP19 within these pathways. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I specifically inhibits PKC. By inhibiting PKC, this compound can prevent the phosphorylation and activation of proteins downstream or associated with PKC, potentially including HMP19. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Go 6983 is another PKC inhibitor. As with other PKC inhibitors, by reducing PKC activity, Go 6983 can decrease the functional activity of proteins regulated by PKC, including HMP19 if it is part of the PKC regulated pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. PI3K is involved in many cellular functions, including those that may regulate the activity of proteins like HMP19. Inhibition of PI3K can lead to a decrease in HMP19 activity by altering the phosphoinositide-dependent signaling pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor. It can inhibit the phosphoinositide 3-kinase pathway, potentially affecting the activity of proteins that are regulated by this pathway, which could include HMP19. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $90.00 $240.00 | 17 | |
Ro-31-8220 inhibits PKC, and by doing so, it can decrease the phosphorylation and subsequent function of proteins that are regulated by PKC, potentially including HMP19. | ||||||
Ruboxistaurin | 169939-94-0 | sc-507364 | 25 mg | $1080.00 | ||
Ruboxistaurin selectively inhibits PKCβ, which is involved in signaling pathways that could regulate the function of proteins like HMP19. By inhibiting PKCβ, ruboxistaurin can reduce the phosphorylation and activity of HMP19. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, and by inhibiting this kinase, it can downregulate the MAPK/ERK pathway, potentially leading to decreased activity of proteins that are regulated by this pathway, including HMP19. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, this compound can affect the activity of proteins that are regulated through the p38 MAPK signaling pathway, potentially leading to a reduction in HMP19 function. | ||||||